Tempus AI (NASDAQ:TEM) Downgraded to “Hold” Rating by Wolfe Research

Wolfe Research lowered shares of Tempus AI (NASDAQ:TEM) from a strong-buy rating to a hold rating in a report released on Wednesday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on TEM. Guggenheim restated a “buy” rating on shares of Tempus AI in a report on Tuesday. Loop Capital lowered their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a report on Tuesday. Finally, TD Cowen reaffirmed a “buy” rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.55.

Tempus AI Trading Down 11.2 %

TEM stock opened at $55.30 on Wednesday. Tempus AI has a one year low of $22.89 and a one year high of $91.45. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company has a fifty day moving average of $52.29 and a 200-day moving average of $52.27.

Insider Activity at Tempus AI

In other news, EVP Andrew Polovin sold 51,504 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the sale, the executive vice president now owns 246,085 shares in the company, valued at $10,431,543.15. The trade was a 17.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the business’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $35.10, for a total value of $9,301,500.00. Following the sale, the insider now owns 15,218,365 shares of the company’s stock, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,823,701 shares of company stock valued at $320,906,059 in the last 90 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its stake in Tempus AI by 13.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock valued at $80,000 after acquiring an additional 278 shares during the period. First Horizon Advisors Inc. acquired a new position in Tempus AI in the third quarter valued at about $30,000. Geode Capital Management LLC grew its stake in Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after acquiring an additional 539 shares during the period. Operose Advisors LLC acquired a new position in Tempus AI in the fourth quarter valued at about $25,000. Finally, Prestige Wealth Management Group LLC grew its stake in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.